Rabbit Polyclonal CXCL9 antibody. Suitable for ELISA, WB, sELISA, IHC-P, Neut and reacts with Recombinant full length protein - Human, Human samples. Cited in 11 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CXCL9.
ELISA | WB | sELISA | IHC-P | Neut | |
---|---|---|---|---|---|
Human | Predicted | Expected | Predicted | Expected | Expected |
Recombinant full length protein - Human | Tested | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes To detect hOPG by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with suitable detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hOPG. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes To yield one-half maximal inhibition [ND50] of the biological activity of hMIG (100.00 ng/ml), a concentration of 5.0 - 7.0 Âμg/ml of this antibody is required |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Select an associated product type
Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3.
CMK, MIG, SCYB9, CXCL9, C-X-C motif chemokine 9, Gamma-interferon-induced monokine, Monokine induced by interferon-gamma, Small-inducible cytokine B9, HuMIG
Rabbit Polyclonal CXCL9 antibody. Suitable for ELISA, WB, sELISA, IHC-P, Neut and reacts with Recombinant full length protein - Human, Human samples. Cited in 11 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CXCL9.
Although some customers have been successful in IHC we no longer batch test in this application.
CXCL9 also known as MIG (monokine induced by gamma interferon) is a small cytokine protein with a molecular weight of approximately 13 kDa. CXCL9 exhibits strong chemotactic properties and is secreted by various cells including endothelial cells macrophages and fibroblasts upon stimulation by interferon-gamma. Its expression primarily occurs in inflamed tissues and is associated with immune responses. Researchers often use tools like a CXCL9 ELISA kit or CXCL9 test to measure its expression levels in biological samples aiding in understanding its role in various conditions.
This cytokine plays a pivotal role in the immune system by regulating leukocyte trafficking. CXCL9 exerts its function through binding to the CXCR3 receptor attracting T cells towards sites of inflammation or infection. This interaction is significant in mediating immune surveillance and host defense. CXCL9 does not form part of a larger protein complex but its chemokine activity is critical for immune system coordination. Scientific studies often highlight its involvement through CXCL9 function and expression analysis.
CXCL9 significantly influences the chemokine signaling pathway and the Th1-type adaptive immune response. Within these pathways it interacts closely with other chemokines like CXCL10 and CXCL11 which also bind to the CXCR3 receptor. These pathways highlight the coordinated mobilization of T cells during immune challenges and inflammation emphasizing how CXCL9 is often examined alongside these related chemokines in research settings.
CXCL9 is notably associated with autoimmune diseases such as rheumatoid arthritis and inflammatory conditions like psoriasis. Its elevated expression is often observed in affected tissues contributing to disease pathogenesis through T cell migration and activation. In these contexts CXCL9 is frequently examined alongside other pro-inflammatory cytokines such as interferon-gamma and TNF-alpha which are known to modulate its expression and activity impacting disease progression and therapeutic strategies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Detection of hMIG (human Monokine induced by Interferon-Gamma) by sandwich ELISA (100 μl/well antibody solution). ab9720 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hMIG.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com